|
LT3286181T
(lt)
|
2015-04-22 |
2021-04-26 |
Rigel Pharmaceuticals, Inc. |
Pirazolo junginiai ir junginių gamybos bei naudojimo būdas
|
|
AU2017222958B2
(en)
*
|
2016-02-25 |
2019-07-18 |
Asceneuron S. A. |
Glycosidase inhibitors
|
|
TWI794171B
(zh)
|
2016-05-11 |
2023-03-01 |
美商滬亞生物國際有限公司 |
Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
|
|
TWI808055B
(zh)
|
2016-05-11 |
2023-07-11 |
美商滬亞生物國際有限公司 |
Hdac 抑制劑與 pd-1 抑制劑之組合治療
|
|
JP7170634B2
(ja)
|
2016-10-26 |
2022-11-14 |
ライジェル ファーマシューティカルズ， インコーポレイテッド |
Ｉｒａｋ阻害剤としての使用のためのオキサゾール誘導体およびその調製のための方法
|
|
ES2946001T3
(es)
|
2016-10-26 |
2023-07-11 |
Rigel Pharmaceuticals Inc |
Compuestos de pirazol amida como inhibidores de IRAK
|
|
AU2017363313B2
(en)
*
|
2016-11-22 |
2021-06-24 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of interleukin-1 receptor-associated kinases and uses thereof
|
|
MX394556B
(es)
*
|
2017-02-01 |
2025-03-24 |
Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd |
Derivados de n1-(4-(5-(ciclopropilmetil)-1-metil-1h-pirazol-4-il) piridin-2-il) ciclohexano-1,4-diamina y compuestos relacionados como inhibidores de ck1 y/o irak1 para tratar cáncer.
|
|
TW202340194A
(zh)
|
2017-02-16 |
2023-10-16 |
美商基利科學股份有限公司 |
吡咯并[1,2-b]嗒𠯤衍生物
|
|
CN110831937A
(zh)
*
|
2017-05-02 |
2020-02-21 |
韩国化学研究院 |
嘧啶衍生物化合物、其光学异构体或其药学上可接受的盐及包含其为有效成分的Tyro3相关疾病的预防或治疗用组合物
|
|
US20210145771A1
(en)
*
|
2017-07-03 |
2021-05-20 |
Glaxosmithkline Intellectual Property Development Limited |
N-(3-(2-(4-chlorophenoxy)acetamido)bicyclo[1.1.1] pentan-1-yl)-2-cyclobutane-1- carboxamide derivatives and related compounds as atf4 inhibitors for treating cancer and other diseases
|
|
CN118239937A
(zh)
*
|
2017-08-09 |
2024-06-25 |
戴纳立制药公司 |
化合物、组合物及方法
|
|
DK3676297T3
(da)
|
2017-09-01 |
2023-08-14 |
Denali Therapeutics Inc |
Forbindelser, sammensætninger og fremgangsmåder
|
|
US11358948B2
(en)
|
2017-09-22 |
2022-06-14 |
Kymera Therapeutics, Inc. |
CRBN ligands and uses thereof
|
|
WO2019060742A1
(en)
|
2017-09-22 |
2019-03-28 |
Kymera Therapeutics, Inc |
AGENTS FOR DEGRADING PROTEINS AND USES THEREOF
|
|
IL315310A
(en)
|
2017-12-26 |
2024-10-01 |
Kymera Therapeutics Inc |
Irak degraders and uses thereof
|
|
WO2019140380A1
(en)
|
2018-01-12 |
2019-07-18 |
Kymera Therapeutics, Inc. |
Protein degraders and uses thereof
|
|
WO2019140387A1
(en)
|
2018-01-12 |
2019-07-18 |
Kymera Therapeutics, Inc. |
Crbn ligands and uses thereof
|
|
WO2020010177A1
(en)
|
2018-07-06 |
2020-01-09 |
Kymera Therapeutics, Inc. |
Tricyclic crbn ligands and uses thereof
|
|
WO2020010227A1
(en)
|
2018-07-06 |
2020-01-09 |
Kymera Therapeutics, Inc. |
Protein degraders and uses thereof
|
|
TWI842978B
(zh)
|
2018-07-13 |
2024-05-21 |
美商基利科學股份有限公司 |
衍生物
|
|
TWI727392B
(zh)
*
|
2018-08-13 |
2021-05-11 |
美商基利科學股份有限公司 |
噻二唑irak4抑制劑
|
|
CA3119773A1
(en)
|
2018-11-30 |
2020-06-04 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
|
US12091392B2
(en)
|
2019-02-13 |
2024-09-17 |
Denali Therapeutics Inc. |
Compounds, compositions and methods
|
|
MA54953A
(fr)
|
2019-02-13 |
2021-12-22 |
Denali Therapeutics Inc |
Composés, compositions et procédés
|
|
PH12022500002A1
(en)
|
2019-06-28 |
2023-04-03 |
Kymera Therapeutics Inc |
Irak degraders and uses thereof
|
|
WO2021011868A1
(en)
|
2019-07-17 |
2021-01-21 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
|
PE20220970A1
(es)
|
2019-08-30 |
2022-06-10 |
Rigel Pharmaceuticals Inc |
Compuestos de pirazol, formulaciones de los mismos y un metodo para usar los compuestos y/o formulaciones
|
|
WO2021119159A1
(en)
|
2019-12-10 |
2021-06-17 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
|
KR20220145325A
(ko)
|
2019-12-17 |
2022-10-28 |
카이메라 쎄라퓨틱스 인코포레이티드 |
Irak 분해제 및 이의 용도
|
|
EP4076524A4
(en)
|
2019-12-17 |
2023-11-29 |
Kymera Therapeutics, Inc. |
IRAQ DEGRADERS AND USES THEREOF
|
|
TW202210483A
(zh)
|
2020-06-03 |
2022-03-16 |
美商凱麥拉醫療公司 |
Irak降解劑之結晶型
|
|
CN116867758A
(zh)
|
2020-12-30 |
2023-10-10 |
凯麦拉医疗公司 |
Irak降解剂和其用途
|
|
US12171768B2
(en)
|
2021-02-15 |
2024-12-24 |
Kymera Therapeutics, Inc. |
IRAK4 degraders and uses thereof
|
|
US12357623B2
(en)
|
2021-03-03 |
2025-07-15 |
Rigel Pharmaceuticals, Inc. |
Method for treating a disease or condition using a pyrazole compound or formulation thereof
|
|
EP4320103A1
(en)
*
|
2021-04-09 |
2024-02-14 |
Quanta Therapeutics, Inc. |
Pyrimidine based ras modulators and uses thereof
|
|
KR20240020735A
(ko)
|
2021-05-07 |
2024-02-15 |
카이메라 쎄라퓨틱스 인코포레이티드 |
Cdk2 분해제 및 그 용도
|
|
CA3236265A1
(en)
|
2021-10-29 |
2023-05-04 |
William Leong |
Irak4 degraders and synthesis thereof
|
|
CN116514769B
(zh)
*
|
2022-01-21 |
2024-02-27 |
中国药科大学 |
4-羟基嘧啶-5-甲酰腙衍生物、制备方法、药物组合物和应用
|
|
CA3243560A1
(en)
|
2022-01-31 |
2023-08-03 |
Kymera Therapeutics, Inc. |
Iraqi Degradation Agents and Their Uses
|
|
CA3243798A1
(en)
|
2022-02-09 |
2023-08-17 |
Quanta Therapeutics, Inc. |
Kras Modulators and Their Uses
|
|
IL315677A
(en)
|
2022-03-23 |
2024-11-01 |
Rigel Pharmaceuticals Inc |
Pyrimid-2-yl-pyrazole compounds as irak inhibitors
|
|
WO2023230190A1
(en)
|
2022-05-25 |
2023-11-30 |
Quanta Therapeutics, Inc. |
Pyrimidine based modulators and uses thereof
|
|
KR20260041941A
(ko)
|
2023-03-15 |
2026-03-27 |
콴타 테라퓨틱스, 인크. |
Kras 조절 인자 및 이의 용도
|
|
CN117924102A
(zh)
*
|
2024-01-23 |
2024-04-26 |
成都伊诺达博医药科技有限公司 |
一种微管亲和力调节激酶抑制剂中间体的制备方法
|